Cambridge Oncometrix Company
Cambridge Oncometrix aims to save lives by enabling the early detection of prostate cancer - a condition that affects 1 in 7 men on the planet. The company develops a non-invasive risk stratification test for prostate cancer. The laboratory test will be capable of accurately selecting men for mpMRI-guided biopsy.
Technology:
AgeTech Companies
Industry:
Diagnostics
Headquarters:
Haverhill, Suffolk, United Kingdom
Founded Date:
2012-06-12
Employees Number:
1-10
Funding Status:
Seed
Total Funding:
$1,731,168.00
Estimated Revenue:
Less than $1M
Last Funding Type:
Grant
Register and Claim Ownership